Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2013 - 2025)

Viridian Therapeutics, Inc.\DE's Other financing activities history runs 12 years deep, the most recent figure standing at $287.9 million for Q4 2025.

• On a quarterly basis, Other financing activities rose 176.09% year-over-year to $287.9 million in Q4 2025; TTM through Mar 2026 was $287.4 million, a 4028.61% increase from a year earlier, with the FY2025 full-year figure at $289.1 million, up 5308.91% from the prior year.
• Other financing activities climbed to $287.9 million in Q4 2025 per VRDN's latest filing, from -$498000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $383.4 million in Q3 2024 and bottomed at -$378.4 million in Q4 2024.
• The 5-year median for Other financing activities is $908000.0 (2022), against an average of $19.7 million.
• Across the five-year window, Other financing activities plunged 1035.13% in 2023 and surged 4615.29% in 2024, its largest moves.
• Year by year, Other financing activities stood at -$900000.0 in 2021, then gained by 19.44% to -$725000.0 in 2022, then plunged by 1071.17% to -$8.5 million in 2023, then plunged by 4356.54% to -$378.4 million in 2024, then surged by 176.09% to $287.9 million in 2025.
• Per Business Quant, the three latest VRDN Other financing activities figures stand at $287.9 million (Q4 2025), -$498000.0 (Q3 2025), and $1.6 million (Q1 2025).